Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma
Richard T Maziarz, Edmund K Waller, Ulrich Jaeger, Isabelle Fleury, Joseph McGuirk, Harald Holte, Samantha Jaglowski, Stephen J Schuster, Michael R Bishop, Jason R Westin, Stephan Mielke, Takanori Teshima, Veronika Bachanova, Stephen R Foley, Peter Borchmann, Gilles A Salles, Jie Zhang, Ranjan Tiwari, Lida B Pacaud, Qiufei Ma Show all
Blood Advances | AMER SOC HEMATOLOGY | Published : 2020
The JULIET phase 2 trial evaluated a single infusion of tisagenlecleucel in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The objective of the current analysis was to evaluate patient-reported health-related quality of life (HRQoL) with a median follow-up of 19.3 months among patients infused with a single dose of tisagenlecleucel. Patients enrolled were ≥18 years of age with r/r DLBCL after ≥2 lines of therapy and had either undergone a failed autologous stem cell transplant or were ineligible for the procedure. Two validated HRQoL instruments, Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and Short Form-36 (SF-36) Health Survey, were use..View full abstract
This study was supported and the editing of the manuscript was funded by Novartis Pharmaceuticals Corporation.